...to severe vasomotor symptoms from baseline to week 12 vs. placebo (80% vs. 60%, p<0.05). Mithra...
...Menopause Society meeting in Vancouver in June. Donesta comprises estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...patient satisfaction and safety Status: Phase II data Milestone: Additional Phase II data (6/2018) Jaime De Leon Donesta Mithra Pharmaceuticals S.A....

...top-line data in late 1Q18. Donesta is an oral estetrol (E4), a human fetal steroid. Mithra Pharmaceuticals S.A....
...metabolism and bone metabolism markers Status: Completed Phase II enrollment Milestone: Phase II data (1Q18) Allison Johnson Donesta Mithra Pharmaceuticals S.A. E4...

...estetrol is in Phase II to treat vasomotor menopause symptoms, with top-line data expected 1Q18. Mithra...
...is eligible for development, regulatory and commercialization milestones in the low, double-digit millions. Fuji and Mithra...
...Phase III development of the candidate in Japan. The companies did not respond to inquiries. Mithra Pharmaceuticals S.A....

...On June 21, women’s health company Mithra Pharmaceuticals S.A (Euronext:MITRA) raised €26.1 million ($29.2 million) through...
...underwritten by KBC Securities , Degroof Petercam and Kempen & Co. Mithra Pharmaceuticals S.A. (Euronext:MITRA), Liege, Belgium Alicia Parker Mithra Pharmaceuticals S.A....

...Idec New Ventures joined existing investors Texas Pacific Group; Alta Partners; InterWest Partners; MPM Capital; Mithra...

...treatment for WNV and a treatment for lymphoma. MacroGenics investors were Alta Partners; TPG Ventures; Mithra...

...in a series B round led by Alta Partners and TPG Ventures. Other investors included Mithra...

...prior to the IPO); Atlas Venture Partners (19.2%); MVM International (14.1%); Cardinal Partners (10.9%); and Mithra...

...AVE). On March 1, Momenta raised $20.5 million in a series C round. Investors included Mithra...

...complex sugars and glycosylated biomolecules, raised $20.5 million in a series C round. Investors included Mithra...